News and Updates

The FDA cleared the iLet Insulin-Only Bionic Pancreas System for people 6 years of age and older with type 1 diabetes.

Breakthrough T1D staff share their experiences with diabetic eye disease to help raise awareness of the importance of being proactive when it comes to vision health.

FDA approved the Medtronic 780G artificial pancreas system, providing automatic adjustments and corrections to blood-sugar levels.

Aspect and Novo Nordisk announce a partnership, using Aspect’s bioprinting technology and Novo Nordisk’s expertise, to develop treatments for diabetes.

JDRF’s Chief Mission Strategy Officer will leave behind quite a legacy once she steps down from her role at Breakthrough T1D at the end of March 2023.

Meet two type 1 diabetes (T1D) clinical trial participants who are helping improve lives and getting us closer to cures, one study at a time.

Beta cell replacement therapies aim to overcome the obstacles to realize their potential, but several approaches are making them a thing of the past.

The CLVer study found that newly diagnosed individuals on verapamil were making more insulin one year after diagnosis than those on placebo.

There is currently no cure for type 1 diabetes (T1D), but Breakthrough T1D has a strategy to change this and transform the future for everyone with T1D.

This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, held February 22-25, will have 45 presenters who are or were Breakthrough T1D-funded.